News | June 04, 2006

Test Makes Early Risk Stratification Possible

The Elecsys proBNP assay is the first and only natriuretic peptide test to receive FDA clearance for the risk assessment of cardiac events in people who have stable coronary artery disease — nearly 13 million in the U.S.
Available for use on the Roche Elecsys systems and MODULAR ANALYTICS E170 immunoassay analyzers, the test is used as an aid in the diagnosis of individuals suspected of congestive heart failure, and as a marker of risk for patients with acute coronary syndrome (ACS) and congestive heart failure. The immunoassay analyzer has a sample throughput of up to 170 tests per hour and includes tests for thyroid, fertility, anemia, cardiac markers, tumor markers and bone markers, among others.
An early marker of cardiac involvement in these disease processes, proBNP enables physicians to identify at-risk patients, learn more about their cardiac status and determine the best treatment and therapy early on.

Overlay Init